

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement issued by JOINN Laboratories (China) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on 30 August 2023 in relation to the connected transactions contemplated in the Leasing Agreements (the “**Announcement**”). Unless otherwise specified in this announcement, terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to provide further information on the identities of the ultimate beneficial owners of Joinn Biologics Holdings Ltd. As at the date of this announcement, Joinn Biologics Holdings Ltd. was held as to 55% by Mr. Zhou, 26% by Ms. Feng and 19% by Zhou Fengyuan and Zhou Fengyi collectively via other intermediary holding companies. Zhou Fengyi and Zhou Fengyuan are the children of Ms. Feng and Mr. Zhou.

Save as disclosed in this announcement, all information in the Announcement remains unchanged.

By order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yulia
Chairperson

Beijing, the PRC, 5 September 2023

As at the date of this announcement, the Board comprises Ms. Feng Yulia as the Chairperson and Executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as Executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-Executive Directors.